3068 related articles for article (PubMed ID: 17007486)
1. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study.
Sobocki P; Pugliatti M; Lauer K; Kobelt G
Mult Scler; 2007 Sep; 13(8):1054-64. PubMed ID: 17623729
[TBL] [Abstract][Full Text] [Related]
3. Estimating the cost of epilepsy in Europe: a review with economic modeling.
Pugliatti M; Beghi E; Forsgren L; Ekman M; Sobocki P
Epilepsia; 2007 Dec; 48(12):2224-33. PubMed ID: 18088267
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of depression in 1990.
Greenberg PE; Stiglin LE; Finkelstein SN; Berndt ER
J Clin Psychiatry; 1993 Nov; 54(11):405-18. PubMed ID: 8270583
[TBL] [Abstract][Full Text] [Related]
5. Cost of disorders of the brain in Luxembourg.
Bisdorff A; Sobocki P; Cloos JM; Andrée C; Graziano ME;
Bull Soc Sci Med Grand Duche Luxemb; 2006; (3):347-58. PubMed ID: 17209294
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of overactive bladder syndrome in six Western countries.
Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
[TBL] [Abstract][Full Text] [Related]
7. Cost estimates of brain disorders in Belgium.
Schoenen J; Gianni F; Schretlen L; Sobocki P
Acta Neurol Belg; 2006 Dec; 106(4):208-14. PubMed ID: 17323838
[TBL] [Abstract][Full Text] [Related]
8. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
Lundkvist J; Kastäng F; Kobelt G
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
10. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
11. Cost of disorders of the brain in Ireland.
McHugh JC; Murphy RP; Sobocki P
Ir Med J; 2007; 100(7):518-21. PubMed ID: 17886523
[TBL] [Abstract][Full Text] [Related]
12. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
Rotstein Z; Hazan R; Barak Y; Achiron A
Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
[TBL] [Abstract][Full Text] [Related]
13. Cost of disorders of the brain in Europe 2010.
Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
[TBL] [Abstract][Full Text] [Related]
14. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
16. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
17. Costs of nine common mental disorders: implications for curative and preventive psychiatry.
Smit F; Cuijpers P; Oostenbrink J; Batelaan N; de Graaf R; Beekman A
J Ment Health Policy Econ; 2006 Dec; 9(4):193-200. PubMed ID: 17200596
[TBL] [Abstract][Full Text] [Related]
18. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care.
Stant AD; TenVergert EM; Kluiter H; Conradi HJ; Smit A; Ormel J
J Ment Health Policy Econ; 2009 Dec; 12(4):195-204. PubMed ID: 20195007
[TBL] [Abstract][Full Text] [Related]
20. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
Wolfenstetter SB
Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
